Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility.
Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility.
复制标题
DOI：
10.1007/s11886-018-0985-8
复制
发表时间：
2018-05-05
影响因子：
3.7
通讯作者：
Yoon YS
中科院分区：
文献类型：
--
作者：
Lee SJ;Kim KH;Yoon YS
人多能干细胞衍生的内皮细胞（hPSC-ECs）成为心血管再生的重要细胞来源。本文综述了hPSC-ECs的制备方法，并对hPSC-ECs的临床应用研究现状进行了综述。开发了用于将hPSC分化成EC谱系的各种系统。逐步的二维系统现在已经很好地建立起来，其中在特定的发育阶段使用各种生长因子、小分子和涂层材料。此外，研究通过从分化系统中去除不确定的组分，提高分化效率，并证明其直接的血管整合作用，使hPSC-ECs的临床应用取得了显着进展，这与成体干细胞及其体内治疗效果形成对比。最后，通过使用生物材料介导的递送，研究人员将hPSC-EC在缺血组织中的存活期提高到10个月以上，并在组织学水平上描述了体内移植的hPSC-EC的长期行为和安全性。hPSC衍生的EC可以作为治疗晚期心血管疾病的关键细胞来源。在过去的二十年中，在分化系统及其临床相容性方面已经取得了实质性的改进。在不久的将来，完全定义的分化系统的建立和生物材料介导的细胞递送的优势的证明，以及一些额外的临床前研究，将使这种疗法成为治疗那些目前可用疗法无法控制的疾病的重要选择。
Human pluripotent stem cell-derived endothelial cells (hPSC-ECs) emerged as an important source of cells for cardiovascular regeneration. This review summarizes protocols for generating hPSC-ECs and provides an overview of the current state of the research in clinical application of hPSC-derived ECs. Various systems were developed for differentiating hPSCs into the EC lineage. Stepwise two-dimensional systems are now well established, in which various growth factors, small molecules, and coating materials are used at specific developmental stages. Moreover, studies made significant advances in clinical applicability of hPSC-ECs by removing undefined components from the differentiation system, improving the differentiation efficiency, and proving their direct vascular incorporating effects, which contrast with adult stem cells and their therapeutic effects in vivo. Finally, by using biomaterial-mediated delivery, investigators improved the survival of hPSC-ECs to more than 10 months in ischemic tissues and described long-term behavior and safety of in vivo transplanted hPSC-ECs at the histological level. hPSC-derived ECs can be as a critical source of cells for treating advanced cardiovascular diseases. Over the past two decades, substantial improvement has been made in the differentiation systems and their clinical compatibility. In the near future, establishment of fully defined differentiation systems and proof of the advantages of biomaterial-mediated cell delivery, with some additional pre-clinical studies, will move this therapy into a vital option for treating those diseases that cannot be managed by currently available therapies.
登录
查看更多内容
影响因子：
14.8
作者：
Levenberg, Shulamit;Ferreira, Lino S.;Chen-Konak, Limor;Kraehenbuehl, Thomas P.;Langer, Robert
通讯作者：
Langer, Robert
影响因子：
14
作者：
Boopathy, Archana V.;Che, Pao Lin;Somasuntharam, Inthirai;Fiore, Vincent F.;Cabigas, E. Bernadette;Ban, Kiwon;Brown, Milton E.;Narui, Yoshie;Barker, Thomas H.;Yoon, Young-Sup;Salaita, Khalid;Garcia, Andres J.;Davis, Michael E.
通讯作者：
Davis, Michael E.
影响因子：
37.8
作者：
Ong SG;Huber BC;Lee WH;Kodo K;Ebert AD;Ma Y;Nguyen PK;Diecke S;Chen WY;Wu JC
通讯作者：
Wu JC
影响因子：
24
作者：
McDermott, Mary M.;Guralnik, Jack M.;Criqui, Michael H.
通讯作者：
Criqui, Michael H.
影响因子：
17.1
作者：
Anderson JM;Patterson JL;Vines JB;Javed A;Gilbert SR;Jun HW
通讯作者：
Jun HW